{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Polycythemia+Vera&page=8", "query": { "condition": "Polycythemia Vera", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 247, "total_pages": 25, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Polycythemia+Vera&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Polycythemia+Vera&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T08:28:31.266Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04603495", "title": "Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Myelofibrosis", "Primary Myelofibrosis", "Post-polycythemia Vera Myelofibrosis", "Post-essential Thrombocythemia Myelofibrosis" ], "interventions": [ { "name": "Pelabresib", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 430, "start_date": "2021-04-09", "completion_date": "2027-06-30", "has_results": true, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-10-22T08:28:31.266Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Chandler, Arizona • La Jolla, California + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04603495" }, { "nct_id": "NCT00669578", "title": "CC-4047 in Treating Patients With Myelofibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Secondary Myelofibrosis" ], "interventions": [ { "name": "CC-4047", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 77, "start_date": "2008-05", "completion_date": "2019-12-12", "has_results": true, "last_update_posted_date": "2019-12-30", "last_synced_at": "2026-10-22T08:28:31.266Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00669578" }, { "nct_id": "NCT01200498", "title": "Study of SB939 in Subjects With Myelofibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myeloproliferative Disorders" ], "interventions": [ { "name": "SB939", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2010-11", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2014-01-30", "last_synced_at": "2026-10-22T08:28:31.266Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01200498" }, { "nct_id": "NCT00509899", "title": "Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myelofibrosis", "Polycythemia Vera", "Thrombocytosis" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 154, "start_date": "2007-06", "completion_date": "2017-02", "has_results": true, "last_update_posted_date": "2018-03-12", "last_synced_at": "2026-10-22T08:28:31.266Z", "location_count": 2, "location_summary": "Rochester, Minnesota • Houston, Texas", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00509899" }, { "nct_id": "NCT00003816", "title": "Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases", "Nonmalignant Neoplasm", "Unspecified Adult Solid Tumor, Protocol Specific", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "thiotepa", "type": "DRUG" }, { "name": "total-body irradiation", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "4 Years to 70 Years" }, "enrollment_count": 361, "start_date": "1998-10-19", "completion_date": "2019-07-12", "has_results": true, "last_update_posted_date": "2021-08-13", "last_synced_at": "2026-10-22T08:28:31.266Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003816" }, { "nct_id": "NCT00463385", "title": "A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelofibrosis With Myeloid Metaplasia", "Myeloid Metaplasia", "Myelofibrosis" ], "interventions": [ { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Placebo to pomalidomide", "type": "DRUG" }, { "name": "Placebo to prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 88, "start_date": "2007-04-01", "completion_date": "2013-12-31", "has_results": true, "last_update_posted_date": "2019-11-20", "last_synced_at": "2026-10-22T08:28:31.266Z", "location_count": 6, "location_summary": "Los Angeles, California • Rochester, Minnesota • New York, New York + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00463385" }, { "nct_id": "NCT02125318", "title": "A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Thrombocytosis", "Myeloproliferative Neoplasms" ], "interventions": [ { "name": "Anagrelide CR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Galena Biopharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2014-05", "completion_date": "2016-05", "has_results": false, "last_update_posted_date": "2017-02-27", "last_synced_at": "2026-10-22T08:28:31.266Z", "location_count": 11, "location_summary": "Burbank, California • Encinitas, California • Escondido, California + 8 more", "locations": [ { "city": "Burbank", "state": "California" }, { "city": "Encinitas", "state": "California" }, { "city": "Escondido", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Aventura", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02125318" }, { "nct_id": "NCT03222609", "title": "A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelofibrosis (MF)" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Navitoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 191, "start_date": "2017-10-31", "completion_date": "2025-01-29", "has_results": true, "last_update_posted_date": "2026-01-20", "last_synced_at": "2026-10-22T08:28:31.266Z", "location_count": 33, "location_summary": "Birmingham, Alabama • Cerritos, California • Duarte, California + 27 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Cerritos", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03222609" }, { "nct_id": "NCT07362225", "title": "MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Polycythemia Vera", "ET (Essential Thrombocythemia)", "Polycythemia Vera (PV)", "Essential Thrombocythemia (ET)", "Primary Myelofibrosis (MF)", "Primary Myelofibrosis (PMF)", "Myelofibrosis", "Myelofibrosis (MF)", "Myelofibrosis, Primary", "Myelofibrosis, Post ET", "Myelofibrosis, Post PV", "Myelofibrosis (PMF)", "Myelofibrosis，MF", "Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis", "Myelofibrosis Due to and Following Polycythemia Vera", "Myelofibrosis Transformation in Essential Thrombocythemia", "Myelofibrosis With High Molecular Risk Mutations", "MF", "Secondary Myelofibrosis", "Secondary Myelofibrosis in Myeloproliferative Disease", "Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis)", "Post-Polycythemia Vera Myelofibrosis", "Post-polycythemia Vera Myelofibrosis (PPV-MF)", "Post-polycythemia Vera Myelofibrosis (Post-PV MF)", "Post-polycythemia Vera Myelofibrosis(Post-PV MF)", "Post-PV MF", "Post-Essential Thrombocythemia Myelofibrosis", "Post-essential Thrombocythemia Myelofibrosis (PET-MF)", "Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)", "Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)", "Post-ET MF", "Pre-fibrotic Myelofibrosis", "Myeloproliferative Disorder", "Myeloproliferative Disorders", "Myeloproliferative Disorders (MPD)", "Myeloproliferative Neoplasms (MPNs)", "Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis", "Myeloproliferative Neoplasm With 10% Blasts or Higher", "Myeloproliferative Neoplasms", "MPN", "MPN (Myeloproliferative Neoplasms)", "MPN-associated Myelofibrosis", "Myeloproliferative Neoplasm, Unclassifiable", "Myeloproliferative Neoplasm, Not Otherwise Specified", "Accelerated Phase MPN", "Accelerated Phase Myeloproliferative Neoplasm", "Blast Phase MPN", "Blast Phase Myeloproliferative Neoplasm", "Thrombocythemia Myelofibrosis (PET-MF)", "Thrombocythemia, Essential", "Thrombocythemia, Hemorrhagic", "Agnogenic Myeloid Metaplasia", "Chronic Idiopathic Myelofibrosis", "Idiopathic Myelofibrosis", "MDS/MPN Crossover Syndromes" ], "interventions": [], "intervention_types": [], "sponsor": "MPN Research Foundation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5000, "start_date": "2025-09-26", "completion_date": "2035-09-08", "has_results": false, "last_update_posted_date": "2026-01-23", "last_synced_at": "2026-10-22T08:28:31.266Z", "location_count": 2, "location_summary": "Chicago, Illinois • New York, New York", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07362225" }, { "nct_id": "NCT00054340", "title": "Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Graft Versus Host Disease", "Leukemia", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "65 Years", "sex": "ALL", "summary": "Up to 65 Years" }, "enrollment_count": null, "start_date": "2002-10", "completion_date": "2006-09", "has_results": false, "last_update_posted_date": "2010-05-14", "last_synced_at": "2026-10-22T08:28:31.266Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00054340" } ] }